STAT | Reporting from the frontiers of health and medicine Follow Opinion: Mifepristone court ruling makes drug development riskier for everyone The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón. https://www.statnews.com/2026/05/04/mifepristone-supreme-court-fda-biotech-pharma/ statnews.com
